Current Headlines

1. Panome Bio Introduces MassID™ A Major Advance In Untargeted Metabolomics Data Analysis For Biomarker Discovery And Drug Development 2/25/2026

   Panome Bio, a leading multi-omics contract research organization, today announced the launch of MassID™, a cloud-based computational platform designed to dramatically improve how researchers process and interpret untargeted LC/MS metabolomics data. MassID is described in a new bioRxiv preprint titled "MassID provides near complete annotation of metabolomics data with identification probabilities."

2. FDA Accepts Viatris Supplemental New Drug Application For MR-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia 2/25/2026

   Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia.

3. MindRank Announces First Patient Dosed In Phase III Trial Of AI-Designed Oral GLP-1 Receptor Agonist MDR-001 2/25/2026

   MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III clinical trial of MDR-001, its AI-designed oral small-molecule GLP-1 receptor agonist (GLP-1RA) for the treatment of obesity and type 2 diabetes in China.

4. Helsinn Healthcare & InVirtuoLabs Sign A Strategic Collaboration In AI-Driven Drug Discovery 2/25/2026

   Helsinn Healthcare SA (Helsinn), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and In Virtuo Laboratories SA (InVirtuoLabs), a Lugano-based drug discovery company specializing in AI-powered generative chemistry, today announced a strategic collaboration to discover and develop novel small-molecule therapeutics.

5. IQVIA Signs Agreement To Acquire Drug Discovery Assets From Charles River Laboratories, Expanding End-To-End Drug Discovery Capabilities 2/25/2026

   IQVIA Holdings Inc. (“IQVIA”), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories.

6. Lupin Announces The Approval And Launch Of Brivaracetam Oral Solution In The United States 2/24/2026

   Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL.

7. Draper And Partners Awarded ARPA-H Funding To Develop New In Silico Models Of Human Physiology For Drug Development 2/24/2026

   Draper recently received an up to $26.7 million other transaction award (OTA) from the Advanced Research Projects Agency for Health (ARPA-H). The award supports the agency's Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program, which will develop a new generation of in silico models of human physiology based on data from New Approach Methodologies (NAMs) to inform the drug development process.

8. Angelini Pharma And Quiver Bioscience Announce Strategic Research Collaboration And Licensing Agreement To Discover And Advance Novel Therapeutics For Genetic Epilepsies 2/23/2026

   Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies.

9. FDA Accepts New Drug Application For Genentech's Giredestrant In ESR1-Mutated, ER-Positive Advanced Breast Cancer 2/20/2026

   Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application for giredestrant, an investigational oral therapy, in combination with everolimus for the treatment of adult patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence or progression on a prior endocrine-based regimen.

10. Sygnature Discovery Unveils Strategic Rebrand To Cement Status As A Global Drug Discovery Partner 2/19/2026

    Sygnature Discovery, a leading drug discovery contract research organisation (CRO), has today announced a strategic brand relaunch, including a new website, cementing its position as a global drug discovery partner.